{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T17:17:00Z","timestamp":1786987020633,"version":"build-2736575974"},"reference-count":16,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T00:00:00Z","timestamp":1760313600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.clml.2025.10.010","type":"journal-article","created":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:41:41Z","timestamp":1760546501000},"page":"e283-e291","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9060-8911","authenticated-orcid":false,"given":"Javier","family":"Munoz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allison","family":"Rosenthal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0456-5618","authenticated-orcid":false,"given":"Andrew","family":"Ip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6557-4027","authenticated-orcid":false,"given":"Justin M.","family":"Darrah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tongsheng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guihua","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Mutebi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tychell","family":"Branchcomb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Ding","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindit","family":"Chhibber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fernando Rivas","family":"Navarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malene","family":"Risum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad","family":"Atiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha","family":"Brodkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abualbishr","family":"Alshreef","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diala","family":"Harb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariana","family":"Sacchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Hoehn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmin H.","family":"Karimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2025.10.010_bib0001","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1002\/ajh.26151","article-title":"2021 Update on Diffuse large B cell lymphoma: a review of current data and potential applications on risk stratification and management","volume":"96","author":"Susanibar-Adaniya","year":"2021","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2025.10.010_bib0002","article-title":"Management considerations for patients with primary refractory and early relapsed diffuse large B-cell lymphoma","volume":"43","author":"Duarte","year":"2023","journal-title":"Am Soc Clin Oncol Educ Book"},{"key":"10.1016\/j.clml.2025.10.010_bib0003","doi-asserted-by":"crossref","first-page":"8553","DOI":"10.3390\/ijms21228553","article-title":"Novel therapies for relapsed or refractory diffuse large B-cell lymphoma","volume":"21","author":"Harris","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.clml.2025.10.010_bib0004","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.1038\/s41591-023-02572-5","article-title":"Axicabtagene ciloleucel as second-line therapy in large B cell lymphoma ineligible for autologous stem cell transplantation: a phase 2 trial","volume":"29","author":"Houot","year":"2023","journal-title":"Nat Med"},{"key":"10.1016\/j.clml.2025.10.010_bib0005","doi-asserted-by":"crossref","first-page":"e181","DOI":"10.1016\/j.clml.2024.01.010","article-title":"Real-world survival, healthcare resource utilization, and costs among U.S. Elderly patients with diffuse large B-cell lymphoma (DLBCL) treated with R-GemOx in the relapsed\/refractory setting","volume":"24","author":"Garg","year":"2024","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"10.1016\/j.clml.2025.10.010_bib0006","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1080\/10428194.2021.1901090","article-title":"Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation","volume":"62","author":"Cazelles","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2025.10.010_bib0007","year":"2024"},{"key":"10.1016\/j.clml.2025.10.010_bib0008","doi-asserted-by":"crossref","first-page":"666","DOI":"10.3390\/jpm14070666","article-title":"The evolving role of bispecific antibodies in diffuse large B-cell lymphoma","volume":"14","author":"Saleh","year":"2024","journal-title":"J Pers Med"},{"key":"10.1016\/j.clml.2025.10.010_bib0009","doi-asserted-by":"crossref","first-page":"2653","DOI":"10.1038\/s41375-024-02410-8","article-title":"Epcoritamab in relapsed\/refractory large B-cell lymphoma: 2-year follow-up from the pivotal EPCORE NHL-1 trial","volume":"38","author":"Thieblemont","year":"2024","journal-title":"Leukemia"},{"issue":"suppl 3","key":"10.1016\/j.clml.2025.10.010_bib0010","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1097\/01.HS9.0000847716.29326.a8","article-title":"Subcutaneous epcoritamab with gemox induced high response rates in patients with relapsed\/refractory diffuse large B-cell lymphoma ineligible for autologous stem cell transplant [abstract P1213]","volume":"6","author":"Wahlin","year":"2022","journal-title":"Hemasphere"},{"key":"10.1016\/j.clml.2025.10.010_bib0011","unstructured":"National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u24c7): B-cell Lymphomas. Version 1.2024. 2024. https:\/\/www.nccn.org. Accessed October 31, 2025."},{"key":"10.1016\/j.clml.2025.10.010_bib0012","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1186\/s12874-020-01124-6","article-title":"Performance of unanchored matching-adjusted indirect comparison (MAIC) for the evidence synthesis of single-arm trials with time-to-event outcomes","volume":"20","author":"Jiang","year":"2020","journal-title":"BMC Med Res Methodol"},{"key":"10.1016\/j.clml.2025.10.010_bib0013","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1007\/s12325-023-02775-9","article-title":"Treatment outcomes with standard of care in relapsed\/refractory diffuse large B-cell lymphoma: real-world data analysis","volume":"41","author":"Ip","year":"2024","journal-title":"Adv Ther"},{"key":"10.1016\/j.clml.2025.10.010_bib0014","unstructured":"University of Connecticut. Guidance on secondary analysis of existing data sets. https:\/\/ovpr.uconn.edu\/services\/rics\/irb\/researcher-guide\/secondary-analysis-of-data-sets. Accessed October 31, 2025."},{"key":"10.1016\/j.clml.2025.10.010_bib0015","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1016\/j.jval.2012.05.004","article-title":"Matching-adjusted indirect comparisons: a new tool for timely comparative effectiveness research","volume":"15","author":"Signorovitch","year":"2012","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2025.10.010_bib0016","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s13045-024-01594-x","article-title":"Comparisons of treatment outcomes of epcoritamab versus chemoimmunotherapy, polatuzumab-based regimens, tafasitamab-based regimens, or chimeric antigen receptor T-cell therapy, in third-line or later relapsed\/refractory large B-cell lymphoma","volume":"17","author":"Rosenthal","year":"2024","journal-title":"J Hematol Oncol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042478?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265025042478?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T15:17:30Z","timestamp":1770650250000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265025042478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":16,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["S2152265025042478"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.010","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Epcoritamab Plus Gemcitabine and Oxaliplatin Versus Rituximab Plus Gemcitabine and Oxaliplatin in Transplant-Ineligible Relapsed\/Refractory Diffuse Large B-Cell Lymphoma: A Match-Adjusted Comparative Analysis","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2025.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}